Journal Home > Volume 4 , Issue 3
Genes & Diseases 2017, 4(3): 127-137 https://doi.org/10.1016/j.gendis.2017.07.006
Review Article | Open Access | Issue | Published: 03 August 2017

Neural EGF-like protein 1 (NELL-1): Signaling crosstalk in mesenchymal stem cells and applications in regenerative medicine

Show Author's Information Mikhail Pakvasaa,b,  Alex Alverdyb,c,  Sami Mostafaa,b,  Eric Wangd,  Lucy Fud,  Alexander Lid,  Leonardo Oliveirad,  Aravind Athivirahamd,  Michael J. Leed,  Jennifer Moriatis Wolfd,  Tong-Chuan Hed,  Guillermo A. Ameere,f,g,  Russell R. Reida,b,( )
The University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
Laboratory of Craniofacial Biology and Development, Section of Plastic and Reconstructive Surgery, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA
Rosalind Franklin University, Chicago Medical School, North Chicago, IL 60064, USA
Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA
Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA
Center for Advanced Regenerative Engineering, Northwestern University, Evanston, IL 60208, USA
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

Peer review under responsibility of Chongqing Medical University.

Keywords:
Osteogenic differentiation, Mesenchymal stem cells, Bone tissue engineering, NELL-1, NEL-like protein 1
Cite this article:
Pakvasa M, Alverdy A, Mostafa S, et al. Neural EGF-like protein 1 (NELL-1): Signaling crosstalk in mesenchymal stem cells and applications in regenerative medicine. Genes & Diseases, 2017, 4(3): 127-137. https://doi.org/10.1016/j.gendis.2017.07.006
Download citation
EndNote(RIS)
BibTeX

124

Views

2

Downloads

Citations

22

Crossref

N/A

WoS

25

Scopus

0

CSCD

Abstract About this article

Bone tissue regeneration holds the potential to solve both osteoporosis and large skeletal defects, two problems associated with significant morbidity. The differentiation of mesenchymal stem cells into the osteogenic lineage requires a specific microenvironment and certain osteogenic growth factors. Neural EGF Like-Like molecule 1 (NELL-1) is a secreted glycoprotein that has proven, both in vitro and in vivo, to be a potent osteo-inductive factor. Furthermore, it has been shown to repress adipogenic differentiation and inflammation. NELL-1 can work synergistically with other osteogenic factors such as Bone Morphogenic Protein (BMP) −2 and −9, and has shown promise for use in tissue engineering and as a systemically administered drug for the treatment of osteoporosis. Here we provide a comprehensive up-to-date review on the molecular signaling cascade of NELL-1 in mesenchymal stem cells and potential applications in bone regenerative engineering.

Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 24 July 2017
Accepted: 27 July 2017
Published: 03 August 2017
Issue date: September 2017

Copyright

© 2017, Chongqing Medical University.

Acknowledgements

Research in the authors’ laboratories was supported in part by research grants from the National Institutes of Health (AT004418, DE020140 to TCH and RRR), the US Department of Defense (OR130096 to JMW), the Scoliosis Research Society (TCH and MJL), and the 973 Program of the Ministry of Science and Technology (MOST) of China (# 2011CB707906 to TCH). MP and SM were recipients of the Pritzker Summer Research Fellowship funded through the National Institute of Health (NIH) T-35 training grant (NIDDK) #T35DK062719- 30. The reported work was also supported in part by The University of Chicago Cancer Center Support Grant (P30CA014599) and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1 TR000430. Funding sources were not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return